Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Epigenomics gets Euros1.1 million for cancer screening technology:

This article was originally published in Clinica

Executive Summary

The German Ministry for Education and Research (BMBF) has given Berlin firm Epigenomics Euros1.1m ($1.3m) to help support a three-year project to design and develop new techniques for high-throughput early cancer screening based on DNA methylation, a natural "switch" that controls gene expression. "This research will further add to the competitive advantages offered by our DNA methylation based technologies," said Kurt Berlin, the firm's chief scientific officer. Due to start in May 2004, the project aims to develop new methods for detecting cancer early that will complement and further expand Epigenomics' pipeline of methylation based products for diagnostic and pharmacodiagnostic applications, the company said.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts